Insulin Price-Fixing Lawsuit and Settlement

Deadline to Submit: September 2025

The average recovery is running about $150MM.
The law firm representing clients in the settlement is the same law firm that litigated the case. (They know how to qualify you to receive the maximum amount of recovery money.)
It is on contingency basis so you pay nothing until the recovery is approved and received.
All settlements on the insulin price-fixing must be filed by Sept 2025 - the clock is ticking.

You must have 1,000+ employees.
You must have a self-funded health insurance plan for your employees.
A discovery call with the attorney's and your CEO and/or CFO and/or Legal Counsel will determine your ultimate ability to participate in the settlement.

Insulin manufacturers Eli Lilly, Novo Nordisk, and Sanofi, in collaboration with the three largest PBMs - CVS Caremark, Express Scripts, and OptumRx, colluded to artificially inflate insulin prices by negotiating secret rebates in exchange for preferential placement on insurance formularies, effectively passing the increased costs onto patients through higher list prices. This period in question goes back to 2003.
A motion for Class Certification was recently denied.
The attorney group we work with has taken a leading role in the substantive discovery phase, which includes large-scale document review of repositories, robust electronic discovery (ESI), and depositions.
The MDL (Multi-district Litigation) is pending before Judge Martinotti in the United States District Court for the District of New Jersey. Our team has handled many cases before this Court, with a proven track record in the most complex cases.

Generic Drug Manufacturers (over 40 of them) were involved in widespread collusion to inflate prices and artificially allocate market share.
Collusion occurred through direct interactions between senior executives at industry events, trade shows, dinners, and other social gatherings.
Prices of approximately 80 generic drugs, particularly those used for dermatological conditions, were allegedly inflated due to this collusion.
The MDL is currently before Judge Rufe in the United States District Court for the Eastern District of Pennsylvania.
Several small-scale settlements have already been established, and we anticipate that our clients will have opportunities to participate in or opt out, as the case may be, depending on the specific circumstances. However, from a timing perspective, all unfiled claims should be filed presently to ensure full participation and evaluation of options.

The attorney group we work with operates on a contingency basis. This means clients incur no upfront costs and would only recover expenses and fees upon a successful outcome. If the cases are unsuccessful, the client owes us nothing.

Recoveries depend upon obtaining and analyzing specific data relative to each case. However, the potential for significant recovery is clear.
The onboarding process is streamlined to minimize the burden on your team.
Once an engagement is signed, the attorney team will gather and analyze the necessary data with the client's selected points of contact to build a comprehensive damages model and case strategy, including the option to opt in and/or opt out of potential settlements as they arise.

Since our law firm participated in the litigation of this case since 2017, they are the "experts" in how to qualify clients for recovery from the settlement. They have worked with over 300 clients that qualify for this settlement and are therefore the subject matter experts in this case.

We will set up a meeting directly with the attorney group that will be handling your case.
In order to do this, you must book a discovery call so we can pre-screen you.

We are one of several business development firms partnered with the law firm to identify potential claimants for this settlement.
We do the initial screening of potential claimants and then set up the discovery call between the law firm and the claimant's CEO or CFO or legal team.